<code id='F492725F97'></code><style id='F492725F97'></style>
    • <acronym id='F492725F97'></acronym>
      <center id='F492725F97'><center id='F492725F97'><tfoot id='F492725F97'></tfoot></center><abbr id='F492725F97'><dir id='F492725F97'><tfoot id='F492725F97'></tfoot><noframes id='F492725F97'>

    • <optgroup id='F492725F97'><strike id='F492725F97'><sup id='F492725F97'></sup></strike><code id='F492725F97'></code></optgroup>
        1. <b id='F492725F97'><label id='F492725F97'><select id='F492725F97'><dt id='F492725F97'><span id='F492725F97'></span></dt></select></label></b><u id='F492725F97'></u>
          <i id='F492725F97'><strike id='F492725F97'><tt id='F492725F97'><pre id='F492725F97'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:841
          The FDA building -- First Opinion coverage from STAT
          Adobe

          WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

          Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

          advertisement

          To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Biotech incubator Curie.Bio graduates its first startup
          Biotech incubator Curie.Bio graduates its first startup

          ChristophLengauer,co-founderandCSOofCurie.BioVanessaLeroyforSTATCurie.Bio,thenewbiotechinvestmentfir

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          Why Novartis is going to walk from its acquisition of MorphoSys

          MollyFerguson/STATNovartissaidMondaythatitintendstobuyMorphoSysforjustunder$3billion.Thedealwillnotc